April 11, 2025

The American College of Radiology® (ACR®) provided comments to the U.S. Food and Drug Administration (FDA) regarding the agency’s draft guidance to address risk management approaches throughout the lifecycle of AI-enabled medical devices, including radiology AI. The document discusses information that manufacturers should share with FDA reviewers and other relevant stakeholders, including physicians and practices, to help them evaluate and monitor AI tools’ safety and effectiveness.

ACR’s comment letter supported the advancement of safe, effective, and clinically useful AI innovation. The College recommended further specificity in product information provided by manufacturers and regulators regarding clinical end-user qualifications. For example, radiologist end-users of imaging AI tools help mitigate risk because they are qualified to interpret imaging examinations without AI assistance. ACR also recommended various enhancements to the guidance’s content on site-level validation, performance monitoring and AI types with novel oversight considerations.  

For more information about ACR’s AI-related initiatives, visit the ACR DSI website. For questions about AI oversight and digital health policy, contact Michael Peters, ACR Senior Director, Government Affairs.


Related ACR News

  • Supreme Court Upholds Preventive Services Coverage

    ACR commends the Supreme Court’s ruling affirming the constitutionality of the structure and appointment process of the U.S. Preventive Services Task Force.

    Read more
  • ACR Drives Urgency For Medicare Pay Fix in Senate Bill

    ACR highlighted the urgent need for a permanent Medicare physician pay fix in a June 23 letter to U.S. Senate leaders.

    Read more
  • ACR Urges Senate to Reconsider Student Loan Program Changes

    ACR and other medical groups cautioned that the student loan provisions would make medical and dental education less accessible to many qualified individuals.

    Read more